The Parker Institute for Cancer Immunotherapy announced that researchers at Dana-Farber Cancer Institute have joined its network. Dana-Farber brings a team of experts who will collaborate with Parker Institute investigators to enhance and expand research projects and clinical trials. Dana-Farber’s expansive clinical trial capabilities and strong immuno-oncology research approach will complement the current work at the Parker Institute, specifically in checkpoint inhibitor resistance.
Leadership teams at both institutions have worked together to identify projects that support the Parker Institute’s strategic roadmap. Projects include those focused on basic mechanisms underlying checkpoint inhibitor resistance, immune activation, and priming. Clinical research may include trials that integrate checkpoint therapies with cancer vaccines.
“Dana-Farber’s team of outstanding investigators will help accelerate the development of cancer immunotherapies with the greatest chance of impact on patients,” said Jeffrey Bluestone, PhD, CEO and President of the Parker Institute.
The researchers from the Dana-Farber Cancer Institute joining the Parker Institute for Cancer Immunotherapy include Nick -Haining, BCh, BM; Catherine Wu, MD; Philip Kranzusch, PhD; and F. Stephen Hodi, Jr, MD. ■
